Protagenic Therapeutics Stock Probability of Future Stock Price Finishing Under 0.73
| PTIX Stock | USD 0.73 0.08 12.31% |
Protagenic |
Protagenic Therapeutics Target Price Odds to finish below 0.73
The tendency of Protagenic Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move below current price in 90 days |
| 0.73 | 90 days | 0.73 | about 82.1 |
Based on a normal probability distribution, the odds of Protagenic Therapeutics to move below current price in 90 days from now is about 82.1 (This Protagenic Therapeutics probability density function shows the probability of Protagenic Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Protagenic Therapeutics has a beta of -1.63 indicating as returns on its benchmark rise, returns on holding Protagenic Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Protagenic Therapeutics is expected to outperform its benchmark. Additionally Protagenic Therapeutics has an alpha of 0.5509, implying that it can generate a 0.55 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Protagenic Therapeutics Price Density |
| Price |
Predictive Modules for Protagenic Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protagenic Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Protagenic Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Protagenic Therapeutics is not an exception. The market had few large corrections towards the Protagenic Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protagenic Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protagenic Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.55 | |
β | Beta against Dow Jones | -1.63 | |
σ | Overall volatility | 0.1 | |
Ir | Information ratio | 0.03 |
Protagenic Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protagenic Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protagenic Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Protagenic Therapeutics is way too risky over 90 days horizon | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics appears to be risky and price may revert if volatility continues | |
| Protagenic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics currently holds about 8.87 M in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| Protagenic Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of 1.275 Million |
Protagenic Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protagenic Stock often depends not only on the future outlook of the current and potential Protagenic Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protagenic Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.3 M | |
| Cash And Short Term Investments | 4.1 M | |
| Shares Float | 3.3 M |
Protagenic Therapeutics Technical Analysis
Protagenic Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Protagenic Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Protagenic Therapeutics. In general, you should focus on analyzing Protagenic Stock price patterns and their correlations with different microeconomic environments and drivers.
Protagenic Therapeutics Predictive Forecast Models
Protagenic Therapeutics' time-series forecasting models is one of many Protagenic Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Protagenic Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Protagenic Therapeutics
Checking the ongoing alerts about Protagenic Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Protagenic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Protagenic Therapeutics is way too risky over 90 days horizon | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics appears to be risky and price may revert if volatility continues | |
| Protagenic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics currently holds about 8.87 M in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| Protagenic Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of 1.275 Million |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.